Vincent Lo Re III, M.D., M.S.C.E.
Associate Professor of Medicine (Infectious Diseases)
Department: Medicine
Graduate Group Affiliations
Contact information
Center for Clinical Epidemiology and Biostatistics
836 Blockley Hall
423 Guardian Drive
Philadelphia, PA 19104
836 Blockley Hall
423 Guardian Drive
Philadelphia, PA 19104
Fax: 215-349-5111
Publications
Education:
B.S. (Chemistry)
Georgetown University, 1992.
M.D. (Medicine)
University of Pennsylvania, 1997.
M.S.C.E. (Pharmacoepidemiology)
University of Pennsylvania, 2005.
B.S. (Chemistry)
Georgetown University, 1992.
M.D. (Medicine)
University of Pennsylvania, 1997.
M.S.C.E. (Pharmacoepidemiology)
University of Pennsylvania, 2005.
Links
Search PubMed for articles
Center for Clinical Epidemiology and Biostatistics faculty webpage.
Permanent linkSearch PubMed for articles
Center for Clinical Epidemiology and Biostatistics faculty webpage.
Description of CCEB Expertise
Dr. Vincent Lo Re is Assistant Professor of Medicine (Infectious Diseases) and Epidemiology at the University of Pennsylvania, Senior Scholar in the Penn Center for Clinical Epidemiology and Biostatistics, and Co-Director of the Penn Center for AIDS Research HIV/Viral Hepatitis Scientific Working Group. Dr. Lo Re leads a research program that examines the epidemiology of acute and chronic liver diseases in HIV-infected patients. He has conducted population-based and mechanistic studies that have helped to move the field of chronic viral hepatitis and HIV/viral hepatitis coinfection forward in a unique way. Recent research has evaluated end-stage liver disease and liver cancer events among HIV/hepatitis C-coinfected patients; examined how chronic viral hepatitis and HIV/viral hepatitis coinfection influence extra-hepatic outcomes, particularly metabolic bone disease; determined the impact that medications have on acute liver injury and progression of chronic viral hepatitis; and evaluated adherence and adverse effects of antiviral therapies of chronic hepatitis B and C. He has particular expertise in evaluating liver-related and other health outcomes among viral hepatitis-infected patients within large electronic data sources, such as the Veterans Health Administration, Kaiser Permanente Northern California, US Medicaid, US Medicare, and Sentinel. His research has been funded by the National Institute of Allergy and Infectious Diseases, National Institute of Diabetes and Digestive and Kidney Diseases, National Cancer Institute, Agency for Healthcare Research and Quality, Department of Veterans Affairs, and the US Food and Drug Administration. He maintains an active clinical practice devoted to the care of patients with chronic viral hepatitis, particularly those coinfected with HIV. In addition to his clinical and research efforts, he is committed to fostering training in clinical research, teaching classes on HIV/viral hepatitis coinfection, biostatistics, infectious diseases epidemiology, gastrointestinal epidemiology, and patient-centered outcomes research.Description of Content-based Expertise
Chronic viral hepatitis; HIV/hepatitis coinfection; drug-induced liver injuryDescription of Methodology Expertise
Infectious diseases epidemiology; GI epidemiology; pharmacoepidemiology; evaluation of clinical outcomes; population-based and administrative databasesSelected Publications
Lo Re V 3rd, Kallan MJ, Tate J, Localio AR, Lim JK, Goetz MB, Klein MB, Rimland D, Rodriguez-Barradas MC, Butt AA, Gibert CL, Brown ST, Park L, Dubrow R, Reddy KR, Kostman JR, Strom BL, Justice AC: Hepatic decompensation in antiretroviral-treated patients co-infected with HIV and hepatitis C virus compared with hepatitis C virus-monoinfected patients: A cohort study. Ann Intern Med 160(6): 369-79, March 2014.Goldberg DS, Forde KA, Haynes K, Lewis JD, Carbonari DM, Leidl KBF, Nezamzadeh MS, Reddy KR, Roy J, Sha D, Marks AR, De Boer J, Strom BL, Corley DA, Lo Re V 3rd: Population-representative incidence of drug-induced acute liver failure based on an analysis of an integrated healthcare system. Gastroenterology 148(7): 1353-61, June 2015.
Saine ME, Moore TM, Szymczak JE, Bamford LP, Barg FK, Mitra N, Schnittker J, Holmes JH, Lo Re V 3rd: Validation of a modified Berger HIV stigma scale for use among patients with hepatitis C virus (HCV) infection. PLoS One 15(2): e0228471, February 2020.
Saine ME, Szymczak JE, Moore TM, Bamford LP, Barg FK, Schnittker J, Holmes JH, Mitra N, Lo Re V 3rd: Determinants of stigma among patients with hepatitis C virus (HCV) infection. J Viral Hepat 27(11): 1179-89, November 2020.
Torgersen J, Kallan MJ, Carbonari DM, Park LS, Mehta RL, D’Addeo K, Tate JP, Lim JK, Goetz MB, Rodriguez-Barradas MC, Gibert CL, Bräu N, Brown ST, Roy JA, Taddei TH, Justice AC, Lo Re V 3rd: HIV RNA, CD4+ percentage, and risk of hepatocellular carcinoma by cirrhosis status. J Natl Cancer Inst 112(7): 747-755, July 2020.
Kim HN, Newcomb CW, Carbonari DM, Roy JA, Torgersen J, Althoff KN, Kitahata MM, Reddy KR, Lim JK, Silverberg MJ, Mayor AM, Horberg MA, Cachay ER, Kirk GD, Sun J, Hull M, Gill MJ, Sterling TR, Kostman JR, Peters MG, Moore RD, Klein MB, Lo Re V 3rd: Risk of hepatocellular carcinoma with hepatitis B viremia among HIV/HBV-coinfected persons in North America. Hepatology 74(3): 1190-1202, September 2021.
Torgersen J, Newcomb CW, Carbonari DM, Rentsch CT, Park LS, Mezochow A, Mehta RL, Buchwalder L, Tate JP, Bräu N, Bhattacharya D, Lim JK, Taddei TH, Justice AC, Lo Re V 3rd : PI-based HCV DAAs are associated with increased risk of aminotransferase elevations but not hepatic dysfunction or decompensation. J Hepatol 75(6): 1312-1322, December 2021.
Weinstein EJ, Ritchey ME, Lo Re V 3rd: Core concepts in pharmacoepidemiology: Validation of health outcomes of interest within real-world healthcare databases. Pharmacoepidemiol Drug Saf 32(1): 1-8, January 2023.
Lo Re V 3rd, Dutcher SK, Connolly JG, Perez-Vilar S, Carbonari DM, DeFor TA, Djibo DA, Harrington LB, Hou L, Hennessy S, Hubbard RA, Kempner ME, Kuntz JL, McMahill-Walraven CN, Mosley J, Pawloski PA, Petrone AB, Pishko AM, Rogers Driscoll M, Steiner CA, Zhou Y, Cocoros NM: Association of COVID-19 versus influenza with risk of arterial and venous thrombotic events among hospitalized patients. JAMA 328(7): 637-51, August 2022.
Ferrante ND, Newcomb CW, Forde KA, Leonard CE, Torgersen J, Linas BP, Rowan SE, Wyles DL, Kostman JR, Trooskin SB, Lo Re V 3rd: The hepatitis C care cascade during the direct-acting antiviral era in a United States commercially-insured population. Open Forum Infect Dis 9(9): ofac445, September 2022.